ENGOT-ov43/MK-7339/KEYLYNK-001
Trial Description:
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC)
Lead Cooperative Group:
Trial Number:
Disease Site:
Ovarian newly diagnosed
Trial Status:
Closed to Recruitment
Contact person:
ivergote